Head-to-head evidence
HRC0202 vs UF-KURE-BCMA
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
HRC0202
Developed by Hrain Biotechnology Co., Ltd.
NCT04003168 · Phase 1 · status unknown
This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The published report covers seven treated patients, fewer than the study's listed enrollment.
UF-KURE-BCMA
Developed by Kure Cells, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2028 · NCT07611149 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRC0202's landscape · UF-KURE-BCMA's landscape